Valbonne, France, February 27, 2017.
TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe inflammatory and autoimmune diseases as well as transplant rejection, today announces its financial calendar for 2017.
- March 9, 2017: Full-year 2016 financial results (post-market)
- April 26, 2017: Q1 2017 financial information (post-market)
- April 27, 2017: Annual Shareholders’ Meeting
- July 26, 2017: Q2 2017 financial information (post-market)
- September 27, 2017: Half-year 2017 financial results (post-market)
- October 19, 2017: Q3 2017 financial information (post-market)
This schedule is indicative and subject to change.
Shareholders are invited to consult the Investor section of TxCell’s website www.txcell.com, which includes all financial information on the Company.